Cargando…
Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone
BACKGROUND: Different effectiveness profiles among second-generation antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to affect long-term outcome. The aim of this study was to compare the clinical effectiveness of aripiprazole, ziprasidone, a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276055/ https://www.ncbi.nlm.nih.gov/pubmed/30215723 http://dx.doi.org/10.1093/ijnp/pyy082 |
_version_ | 1783377939051577344 |
---|---|
author | Gómez-Revuelta, Marcos Pelayo-Terán, José María Juncal-Ruiz, María Ortiz-García de la Foz, Víctor Vázquez-Bourgon, Javier González-Pinto, Ana Crespo-Facorro, Benedicto |
author_facet | Gómez-Revuelta, Marcos Pelayo-Terán, José María Juncal-Ruiz, María Ortiz-García de la Foz, Víctor Vázquez-Bourgon, Javier González-Pinto, Ana Crespo-Facorro, Benedicto |
author_sort | Gómez-Revuelta, Marcos |
collection | PubMed |
description | BACKGROUND: Different effectiveness profiles among second-generation antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to affect long-term outcome. The aim of this study was to compare the clinical effectiveness of aripiprazole, ziprasidone, and quetiapine in the treatment of first episode of psychosis at 3-year follow-up. METHOD: From October 2005 to January 2011, a prospective, randomized, open-label study was undertaken. Two hundred-two first-episode, drug-naïve patients were randomly assigned to aripiprazole (n=78), ziprasidone (n =62), or quetiapine (n=62) and followed-up for 3 years. The primary effectiveness measure was all cause of treatment discontinuation. In addition, an analysis based on the intention-to-treat principle was conducted in the analysis for clinical efficacy. RESULTS: The overall dropout rate at 3 years reached 19.3%. Treatment discontinuation rates were significantly different among treatment groups (aripiprazole=73.08%, ziprasidone=79.03%, and quetiapine=95.16%) (χ2=11.680; P=.001). Statistically significant differences in terms of nonefficacy, nonadherence, and side effects were observed among treatment groups along the 3-year follow-up determining significant differences in time to all-cause discontinuation (log-rank=32.260; P=.001). Significant differences between treatments were found in the categories of sleepiness/sedation (χ(2)=9.617; P=.008) and increased sleep duration (χ(2)=6.192; P=.004). No significant differences were found in the profile of extrapyramidal symptoms. Patients on aripiprazole were more likely to be prescribed benzodiazepines. CONCLUSIONS: First-episode psychosis patients on quetiapine were more likely to discontinue treatment due to nonefficacy. Identifying different discontinuation patterns may contribute to optimize treatment selection after first episode of psychosis. |
format | Online Article Text |
id | pubmed-6276055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62760552018-12-06 Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone Gómez-Revuelta, Marcos Pelayo-Terán, José María Juncal-Ruiz, María Ortiz-García de la Foz, Víctor Vázquez-Bourgon, Javier González-Pinto, Ana Crespo-Facorro, Benedicto Int J Neuropsychopharmacol Regular Research Articles BACKGROUND: Different effectiveness profiles among second-generation antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to affect long-term outcome. The aim of this study was to compare the clinical effectiveness of aripiprazole, ziprasidone, and quetiapine in the treatment of first episode of psychosis at 3-year follow-up. METHOD: From October 2005 to January 2011, a prospective, randomized, open-label study was undertaken. Two hundred-two first-episode, drug-naïve patients were randomly assigned to aripiprazole (n=78), ziprasidone (n =62), or quetiapine (n=62) and followed-up for 3 years. The primary effectiveness measure was all cause of treatment discontinuation. In addition, an analysis based on the intention-to-treat principle was conducted in the analysis for clinical efficacy. RESULTS: The overall dropout rate at 3 years reached 19.3%. Treatment discontinuation rates were significantly different among treatment groups (aripiprazole=73.08%, ziprasidone=79.03%, and quetiapine=95.16%) (χ2=11.680; P=.001). Statistically significant differences in terms of nonefficacy, nonadherence, and side effects were observed among treatment groups along the 3-year follow-up determining significant differences in time to all-cause discontinuation (log-rank=32.260; P=.001). Significant differences between treatments were found in the categories of sleepiness/sedation (χ(2)=9.617; P=.008) and increased sleep duration (χ(2)=6.192; P=.004). No significant differences were found in the profile of extrapyramidal symptoms. Patients on aripiprazole were more likely to be prescribed benzodiazepines. CONCLUSIONS: First-episode psychosis patients on quetiapine were more likely to discontinue treatment due to nonefficacy. Identifying different discontinuation patterns may contribute to optimize treatment selection after first episode of psychosis. Oxford University Press 2018-09-12 /pmc/articles/PMC6276055/ /pubmed/30215723 http://dx.doi.org/10.1093/ijnp/pyy082 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of CINP. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Regular Research Articles Gómez-Revuelta, Marcos Pelayo-Terán, José María Juncal-Ruiz, María Ortiz-García de la Foz, Víctor Vázquez-Bourgon, Javier González-Pinto, Ana Crespo-Facorro, Benedicto Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone |
title | Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone |
title_full | Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone |
title_fullStr | Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone |
title_full_unstemmed | Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone |
title_short | Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone |
title_sort | long-term antipsychotic effectiveness in first episode of psychosis: a 3-year follow-up randomized clinical trial comparing aripiprazole, quetiapine, and ziprasidone |
topic | Regular Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276055/ https://www.ncbi.nlm.nih.gov/pubmed/30215723 http://dx.doi.org/10.1093/ijnp/pyy082 |
work_keys_str_mv | AT gomezrevueltamarcos longtermantipsychoticeffectivenessinfirstepisodeofpsychosisa3yearfollowuprandomizedclinicaltrialcomparingaripiprazolequetiapineandziprasidone AT pelayoteranjosemaria longtermantipsychoticeffectivenessinfirstepisodeofpsychosisa3yearfollowuprandomizedclinicaltrialcomparingaripiprazolequetiapineandziprasidone AT juncalruizmaria longtermantipsychoticeffectivenessinfirstepisodeofpsychosisa3yearfollowuprandomizedclinicaltrialcomparingaripiprazolequetiapineandziprasidone AT ortizgarciadelafozvictor longtermantipsychoticeffectivenessinfirstepisodeofpsychosisa3yearfollowuprandomizedclinicaltrialcomparingaripiprazolequetiapineandziprasidone AT vazquezbourgonjavier longtermantipsychoticeffectivenessinfirstepisodeofpsychosisa3yearfollowuprandomizedclinicaltrialcomparingaripiprazolequetiapineandziprasidone AT gonzalezpintoana longtermantipsychoticeffectivenessinfirstepisodeofpsychosisa3yearfollowuprandomizedclinicaltrialcomparingaripiprazolequetiapineandziprasidone AT crespofacorrobenedicto longtermantipsychoticeffectivenessinfirstepisodeofpsychosisa3yearfollowuprandomizedclinicaltrialcomparingaripiprazolequetiapineandziprasidone |